NORTHERN NEW JERSEY COMMUNITY CLINICAL ONCOLOGY PROGRAM

新泽西州北部社区临床肿瘤项目(NNJ-CCOP) 为超过4.9项的国家合作临床试验提供通道 新泽西州北部人口最多的9个县有100万人口， 与纽约接壤。在此背景下，哈肯萨克医疗中心 (HMC)每年诊断出1500名新的癌症患者，比 在过去五年里。两位成人的患者数量都显著增加 和儿科肿瘤学。业务量的增加与增长和 医疗中心肿瘤学设施和项目的扩展 为增加研究贡献提供一个完美的背景 接下来的5年。 NNJ-CCOP汇集了一组 合作进行研究的多学科调查人员 来自POG、ECOG、NSABP和URCC。调查人员29人，其中13人 两个以医院为基础的私人执业小组的血液学家/肿瘤学家 为各个年龄段的患者提供服务。他们的成就在这两个方面都是优越的 研究的科学性以及临床试验的收益。 未来五年，总体目标是降低癌症发病率， 发病率和死亡率通过加速转移新开发的 癌症预防、早期发现、治疗、病人管理、 康复和持续护理技术推广到广泛的社区 申请。通过精心设计，如果不是这样，该程序将同样专注于 更多的关注和资源用于癌症控制研究而不是治疗 这两个治疗和癌症控制的双重目标是现成的 匹配患者群体并符合NNJ-CCOP的利益和 能力。 NNJ-CCOP的近期目标是继续我们的强劲增长 治疗试验的比率；通过提供 关于我们的治疗方案菜单的其他研究；以促进更广泛的 社区参与，包括少数群体和服务不足 NCL批准的治疗和癌症控制研究中的人群； 培养与初级保健医生和其他专家的联系 可能有助于癌症控制倡议；并完善癌症控制 数据管理能力，包括使用一系列资源来 确定癌症控制研究项目的潜在候选者。这个 进行前列腺癌预防试验(PCPT)是一项主要的 目标。对于这项研究，CCOP是两个批准的研究中心之一 新泽西。 总之，NNJ-CCOP的跟踪记录表明，有能力 管理复杂的临床研究和癌症控制活动，同时 产生最高质量的数据。NNJ-CCOP拥有设施和 训练有素的专业人员支持癌症治疗和 癌症控制试验。CCOP人员配置模式、协议管理 程序、患者/参与者管理方法、质量控制 机制、药房控制机制、IRB结构和联络都是 支持当前和未来的治疗和 癌症控制活动。 在1994至1999年间，将提供2200多个议定书条目 CCOP临床试验：665项治疗试验和1560项 每年153.5个治疗学分和131.5个癌症控制试验 癌症控制学分。

The Northern New Jersey Community Clinical Oncology Program (NNJ-CCOP) provides access to national cooperative clinical trials for over 4.9 million people in the 9 most populous counties in northern New Jersey and bordering New York. Against this background, the Hackensack Medical Center (HMC) diagnoses 1500 new cancer patients per year, an increase of 30% in the last five years. Patient volumes have increased markedly in both Adult and Pediatric Oncology. Increased volume together with the growth and expansion of the oncology facilities and programs at the Medical Center form a perfect backdrop for increased research contributions during the next 5 years. The NNJ-CCOP brings together the strength and resources of a group of multidisciplinary investigators who collaborate in the conduct of studies from POG, ECOG, NSABP, and URCC. The investigators number 29 including 13 hematologists/oncologists in two hospital-based private practice groups serving patients of all ages. Their accomplishments are superior in both the science of the research as well as accrual to clinical trials. Over the next five years, the overall aim is to reduce cancer incidence, morbidity, and mortality by accelerating the transfer of newly developed cancer prevention, early detection, treatment, patient management, rehabilitation, and continuing care technology to widespread community application. By careful design, the program will focus as much, if not more, attention and resources on cancer control research than treatment These twin objectives of both treatment and cancer control are a ready match for the patient population and fit within NNJ-CCOP interests and capabilities. The immediate goals of the NNJ-CCOP are to continue our strong accrual rate to treatment trials; to increase research activity by offering additional studies on our treatment protocol menu; to facilitate wider community participation, including minority groups and underserved populations in treatment and cancer control research approved by NCl; to cultivate contacts with primary care physicians and other specialists who may contribute to cancer control initiatives; and to refine cancer control data management capabilities, including the use of a range of resources to identify potential candidates for cancer control research projects. The conduct of the Prostate Cancer Prevention Trial (PCPT) is a primary objective. For this study, the CCOP is 1 of 2 approved Study Centers in New Jersey. In summary, the track record of the NNJ-CCOP demonstrates the ability to manage complex clinical research and cancer control activities while producing the highest quality data. The NNJ-CCOP has the facilities and well-trained professional personnel to support both cancer treatment and cancer control trials. The CCOP staffing pattern, protocol management procedures, patient / participant management approaches, quality control mechanisms, pharmacy control mechanisms, IRB structure and liaison are all in place and functioning to support current and future therapeutic and cancer control activities. Between 1994 and 1999, over 2200 protocol entries will be contributed to CCOP clinical trials: 665 entries to treatment trials and 1560 entries to cancer control trials per year for 153.5 treatment credits and 131.5 cancer control credits.